Published in Am J Respir Crit Care Med on June 07, 2007
Interactions between coagulation and complement--their role in inflammation. Semin Immunopathol (2011) 1.46
Endothelial and Microcirculatory Function and Dysfunction in Sepsis. Clin Chest Med (2016) 1.42
Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. J Intensive Care (2014) 1.11
Protective mechanisms of activated protein C in severe inflammatory disorders. Br J Pharmacol (2009) 1.07
Recombinant human activated protein C: current insights into its mechanism of action. Crit Care (2007) 1.06
Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis. Crit Care (2014) 1.02
Activated protein C action in inflammation. Br J Haematol (2009) 0.98
Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care (2010) 0.97
The protein C pathway: implications for the design of the RESPOND study. Crit Care (2007) 0.96
The safety profile of drotrecogin alfa (activated). Crit Care (2007) 0.91
Clinical trials in severe sepsis with drotrecogin alfa (activated). Crit Care (2007) 0.88
Practical aspects of treatment with drotrecogin alfa (activated). Crit Care (2007) 0.87
Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy. Crit Care (2008) 0.82
Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies. Biologics (2009) 0.79
Activated protein C in severe acute pancreatitis without sepsis? Not just yet ... Crit Care (2010) 0.79
Analysis of Risk Factors for Lower-limb Deep Venous Thrombosis in Old Patients after Knee Arthroplasty. Chin Med J (Engl) (2015) 0.78
Evaluation of recombinant activated protein C for severe sepsis at a tertiary academic medical center. Ther Clin Risk Manag (2013) 0.77
Anticoagulant properties of drotrecogin alfa (activated) during hemofiltration in patients with severe sepsis. Crit Care (2009) 0.77
Heparins attenuated histone-mediated cytotoxicity in vitro and improved the survival in a rat model of histone-induced organ dysfunction. Intensive Care Med Exp (2015) 0.76
XPRESS study: heparin in ... not out. Am J Respir Crit Care Med (2008) 0.75
Drotrecogin alfa (activated): surviving sepsis by chance. Am J Respir Crit Care Med (2008) 0.75
8 Inhibitors. Transfus Med Hemother (2009) 0.75
Heparin prophylaxis did not increase mortality and was beneficial in adults with sepsis receiving drotrecogin alfa. ACP J Club (2008) 0.75
Concurrent administration of heparin and activated protein C in a patient with pulmonary embolism and severe sepsis with positive outcome. Indian J Crit Care Med (2009) 0.75
Case report: perioperative use of protein c concentrate for protein C deficiency in THA. Clin Orthop Relat Res (2009) 0.75
Role of clinical evaluation committees in sepsis trials: from 'valid cohort' assessment to subgroup analysis. Crit Care (2009) 0.75
Drotrecogin alpha: a rational approach to the treatment of submassive pulmonary embolism? Crit Care (2011) 0.75
An update on activated protein C (xigris) in the management of sepsis. P T (2010) 0.75
Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med (2012) 9.19
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med (2005) 8.55
Withdrawal of mechanical ventilation in anticipation of death in the intensive care unit. N Engl J Med (2003) 7.32
Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med (2014) 7.07
The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med (2010) 6.69
Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA (2009) 6.55
Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA (2008) 6.29
Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med (2014) 5.70
Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet (2007) 5.23
The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med (2010) 4.64
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA (2003) 4.54
Clinical practice guidelines for support of the family in the patient-centered intensive care unit: American College of Critical Care Medicine Task Force 2004-2005. Crit Care Med (2007) 4.14
Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study. Lancet Infect Dis (2012) 4.07
An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med (2008) 3.98
Early changes in organ function predict eventual survival in severe sepsis. Crit Care Med (2005) 3.97
Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med (2001) 3.95
Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care (2013) 3.90
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med (2005) 3.85
Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet (2002) 3.73
High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury. Chest (2005) 3.58
A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med (2014) 3.56
Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med (2014) 3.37
Fluid challenges in intensive care: the FENICE study: A global inception cohort study. Intensive Care Med (2015) 3.27
Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study. Am J Respir Crit Care Med (2010) 3.21
Early vs late tracheotomy for prevention of pneumonia in mechanically ventilated adult ICU patients: a randomized controlled trial. JAMA (2010) 3.20
The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med (2012) 3.18
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med (2003) 3.18
Challenges in end-of-life care in the ICU. Statement of the 5th International Consensus Conference in Critical Care: Brussels, Belgium, April 2003. Intensive Care Med (2004) 3.16
Intensive care unit quality improvement: a "how-to" guide for the interdisciplinary team. Crit Care Med (2006) 3.15
Usefulness of transcranial echography in patients with decompressive craniectomy: a comparison with computed tomography scan. Crit Care Med (2012) 3.10
Challenges in end-of-life care in the ICU: statement of the 5th International Consensus Conference in Critical Care: Brussels, Belgium, April 2003: executive summary. Crit Care Med (2004) 2.95
Positive-end expiratory pressure reduces incidence of ventilator-associated pneumonia in nonhypoxemic patients. Crit Care Med (2008) 2.87
Efficacy of single-dose antibiotic against early-onset pneumonia in comatose patients who are ventilated. Chest (2013) 2.85
Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study. Crit Care Med (2015) 2.81
In-hospital cardiac arrest: incidence, prognosis and possible measures to improve survival. Intensive Care Med (2006) 2.72
Clinician predictions of intensive care unit mortality. Crit Care Med (2004) 2.65
An outbreak in an intensive care unit of a strain of methicillin-resistant Staphylococcus aureus sequence type 239 associated with an increased rate of vascular access device-related bacteremia. Clin Infect Dis (2007) 2.64
Efficacy and limitation of a chlorhexidine-based decolonization strategy in preventing transmission of methicillin-resistant Staphylococcus aureus in an intensive care unit. Clin Infect Dis (2010) 2.56
Evaluation of patient skin breakdown and comfort with a new face mask for non-invasive ventilation: a multi-center study. Intensive Care Med (2002) 2.46
The Eldicus prospective, observational study of triage decision making in European intensive care units. Part II: intensive care benefit for the elderly. Crit Care Med (2012) 2.46
Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med (2003) 2.44
Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis (2007) 2.44
Quality indicators for end-of-life care in the intensive care unit. Crit Care Med (2003) 2.42
Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 Western European countries. Clin Infect Dis (2009) 2.39
The Italian ECMO network experience during the 2009 influenza A(H1N1) pandemic: preparation for severe respiratory emergency outbreaks. Intensive Care Med (2011) 2.28
Obesity is associated with increased morbidity but not mortality in critically ill patients. Intensive Care Med (2008) 2.27
Developing a new, national approach to surveillance for ventilator-associated events*. Crit Care Med (2013) 2.24
HMGB1 contributes to the development of acute lung injury after hemorrhage. Am J Physiol Lung Cell Mol Physiol (2005) 2.21
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation (2009) 2.20
ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis. Pediatr Crit Care Med (2006) 2.19
Hemodynamic monitoring in shock and implications for management. International Consensus Conference, Paris, France, 27-28 April 2006. Intensive Care Med (2007) 2.18
Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med (2005) 2.12
Diabetes does not alter mortality or hemostatic and inflammatory responses in patients with severe sepsis. Crit Care Med (2010) 2.11
Influence of systemic inflammatory response syndrome and sepsis on outcome of critically ill infected patients. Am J Respir Crit Care Med (2003) 2.10
Prevalence of Venous Thrombosis Following Venovenous Extracorporeal Membrane Oxygenation in Patients With Severe Respiratory Failure. Crit Care Med (2015) 2.07
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med (2003) 2.05
Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome. Am J Respir Crit Care Med (2014) 2.05
Is worsening multiple organ failure the cause of death in patients with severe sepsis? Crit Care Med (2011) 2.04
Euthanasia, therapeutic obstinacy or something else? An Italian case. Intensive Care Med (2005) 2.03
The pulmonary artery catheter: in medio virtus. Crit Care Med (2008) 2.01
Noninvasive versus invasive ventilation for acute respiratory failure in patients with hematologic malignancies: a 5-year multicenter observational survey. Crit Care Med (2011) 1.96
Statin therapy prior to ICU admission: protection against infection or a severity marker? Intensive Care Med (2005) 1.86
Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock. Am J Respir Crit Care Med (2008) 1.82
Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med (2009) 1.80
A meta-analysis of complications and mortality of extracorporeal membrane oxygenation. Crit Care Resusc (2013) 1.77
Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. Am J Respir Crit Care Med (2004) 1.72
Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med (2004) 1.72
Prevalence, management, and outcomes of critically ill patients with prothrombin time prolongation in United Kingdom intensive care units. Crit Care Med (2010) 1.66
Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med (2011) 1.65
Noninvasive ventilation after early extubation in patients recovering from hypoxemic acute respiratory failure: a single-centre feasibility study. Intensive Care Med (2012) 1.63
Adjunctive corticosteroid therapy in pediatric severe sepsis: observations from the RESOLVE study. Pediatr Crit Care Med (2011) 1.60
Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care (2013) 1.60
Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics (2004) 1.60
The Eldicus prospective, observational study of triage decision making in European intensive care units: part I--European Intensive Care Admission Triage Scores. Crit Care Med (2012) 1.59
Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis. Clin J Am Soc Nephrol (2006) 1.59
Restrictive versus liberal transfusion strategies for older mechanically ventilated critically ill patients: a randomized pilot trial. Crit Care Med (2013) 1.59
Diagnostic accuracy of passive leg raising for prediction of fluid responsiveness in adults: systematic review and meta-analysis of clinical studies. Intensive Care Med (2010) 1.58
A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. Crit Care Med (2013) 1.58
Noninvasive positive-pressure ventilation with different interfaces in patients with respiratory failure after abdominal surgery: a matched-control study. Respir Care (2007) 1.57
A multicenter, randomized trial of noninvasive ventilation with helium-oxygen mixture in exacerbations of chronic obstructive lung disease. Crit Care Med (2010) 1.56
Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler (2012) 1.55
The Surviving Sepsis Campaign bundles and outcome: results from the International Multicentre Prevalence Study on Sepsis (the IMPreSS study). Intensive Care Med (2015) 1.55
Ventilator-associated pneumonia: current status and future recommendations. J Clin Monit Comput (2010) 1.54
Drotrecogin alfa (activated) treatment of older patients with severe sepsis. Clin Infect Dis (2003) 1.54
A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med (2015) 1.54
Online vs live methods for teaching difficult airway management to anesthesiology residents. Intensive Care Med (2005) 1.51
Non-invasive ventilation delivered by conventional interfaces and helmet in the emergency department. Eur J Emerg Med (2003) 1.51
Multicenter implementation of a consensus-developed, evidence-based, spontaneous breathing trial protocol. Crit Care Med (2008) 1.51